ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

OSIR Osiris Therape (MM)

18.99
0.00 (0.00%)
27 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Osiris Therape (MM) NASDAQ:OSIR NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 18.99 18.88 19.01 0 01:00:00

Termination of Registration of a Class of Security Under Section 12(b) (15-12b)

29/04/2019 9:13pm

Edgar (US Regulatory)


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

Commission File Number:  

001-32966

 

Osiris Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

7015 Albert Einstein Drive
Columbia, MD 21046
(443) 545-1800
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Stock, $0.001 par value

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

 

Rule 12g-4(a)(1)

x

 

 

 

 

 

Rule 12g-4(a)(2)

o

 

 

 

 

 

Rule 12h-3(b)(1)(i)

x

 

 

 

 

 

Rule 12h-3(b)(1)(ii)

o

 

 

 

 

 

Rule 15d-6

o

 

 

 

 

 

 

 

 

 

 

 

 

Approximate number of holders of record as of the certification or notice date: One (1)

 

Explanatory Note :  Effective April 17, 2019, Papyrus Acquisition Corp., a Maryland corporation, which is a wholly owned subsidiary of Smith & Nephew Consolidated, Inc., a Delaware corporation, which is an indirect wholly owned subsidiary of Smith & Nephew plc, an English public liability company, was merged with and into Osiris Therapeutics, Inc., a Maryland corporation, with Osiris Therapeutics, Inc. continuing as the surviving corporation and thereby being converted from a public corporation into a private corporation.

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, Osiris Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

 

 

 

OSIRIS THERAPEUTICS, INC.

 

 

 

 

 

 

 

 

 

 

 

 

 

Date:

April 29, 2019

 

By:

/s/ Michael Zagger

 

 

 

 

 

Name:

Michael Zagger

 

 

 

 

 

Title:

President

 

 


1 Year Osiris Therapeutics, Inc. Chart

1 Year Osiris Therapeutics, Inc. Chart

1 Month Osiris Therapeutics, Inc. Chart

1 Month Osiris Therapeutics, Inc. Chart